Earlier this year, Johnson & Johnson announced the first major regulatory approval of a vaccine developed by Janssen for the prevention of Ebola. Nikki Withers spoke with the Global Head of Vaccines, Johan Van Hoof, to discover what technologies were used and how they are now being leveraged to develop a vaccine candidate for the prevention of COVID-19.
Ebola virus disease, formerly known as Ebola haemorrhagic fever, is a rare but severe, often fatal, illness in humans. The virus is transmitted to people from wild animals and spreads in humans through human-to-human transmission.1 In 2014, the Janssen Pharmaceutical Companies of Johnson & Johnson committed to accelerating the development of a vaccine regimen for the prevention of Ebola. “Up until 2014, Ebola outbreaks mainly happened in rural areas, but due to the high mortality associated with the virus and the fact that people get ill fairly early onwards, we quickly learned that with the right hygiene measures you could control an epidemic quite well,” said Johan Van Hoof, Global Head of Vaccines at Janssen. However, in 2014 the worst Ebola outbreak to date occurred in West Africa, which caused nearly 30,000 cases and more than 11,000 deaths in 2014-2016.2
“In 2015, I travelled to Sierra Leone and witnessed the devastation that Ebola was inflicting on the people of the country,” said Van Hoof. “Before Ebola, Sierra Leone had one of the fastest growing economies in Africa, well on its way to recovering from a lengthy civil war. People’s aspirations were high. Ebola halted all of that, reminding us just how susceptible human life is to the devastating effects of infectious diseases and how much we still have to learn about our own immune system.”
At the time, Janssen mobilised significant resources and expertise to accelerate the development of a “prime-boost” Ebola vaccine regimen in collaboration with Bavarian Nordic and a host of global partners, including the Biomedical Advanced Research and Development Authority (BARDA) and Europe’s Innovative Medicines Initiative (IMI). The company launched 10 Phase I, II, and III clinical trials for the Ebola vaccine regimen across three continents in just one year.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
The second worst Ebola outbreak on record began in the Democratic Republic of the Congo (DRC) in 2018. It has since caused more than 3,000 cases and over 2,000 deaths – a mortality rate of 65 percent.3 Although this outbreak has now ended, a new one has now been declared, underlying the ongoing public health threat. “The Ebola outbreak in the DRC has reminded us that the threat has not gone away and we have to be prepared,” Van Hoof emphasised.
In May this year, Johnson & Johnson announced that Janssen had received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its investigational Ebola vaccine regimen. This was followed by an announcement in July that the European Commission (EC) had granted Marketing Authorisation for the vaccine. “The approval of our Ebola vaccine symbolises the progress Janssen has made towards achieving our vision of delivering potentially transformational vaccines to communities most at risk of deadly infectious diseases. Not only is it the first vaccine to emerge from our vaccines pipeline, it is also the first approved vaccine to be developed using Janssen’s AdVac® technology,” said Mathai Mammen, Global Head, Janssen Research & Development.
The preventive vaccine regimen includes Ad26. ZEBOV as the first dose, based on Janssen’s AdVac® viral vector technology,4 and MVA-BN-Filo as the second dose, based on Bavarian Nordic’s MVA‑BN® technology, administered approximately eight weeks later.5 Van Hoof explained that the AdVac® technology utilises a non-replicating viral vector strategy in which a virus – in this case adenovirus serotype 26 (Ad26) – is genetically altered so that it cannot replicate in human cells. This vector carries the genetic code of an Ebola virus protein and when the body encounters the antigen, it induces both a long-lasting humoral and cellular immune response against the antigen through the activation of immune cells and production of antibodies. “In the future, if the body encounters the actual pathogen, the body will be able to respond faster and more effectively, as immune cells and antibodies specific to the pathogen will be rapidly available in the body to prevent the pathogen from inducing disease,” he said.
Rapid scale up
Van Hoof noted that Janssen’s technology allows the facilitation of rapid scale up to high capacity and low-cost manufacturing. “We are able to produce manufacturing runs with very high yields. Combining a solid gene technology platform with our manufacturing cell line platform therefore allows us to react swiftly to new threats and be fast in up-scaling. Our hope is that with the approval of this vaccine, there is an extra tool available in the toolbox to fight against the Ebola threats.”
The 2014 outbreak of Ebola in West Africa grew exponentially and overwhelmed healthcare systems. “In less than six years, with the strength of global public-private collaborations, we have an approved Ebola vaccine which could help those most in need, with the ultimate goal of preventing outbreaks before they start,” said Van Hoof.
Further application
The same technology is also being used to develop vaccine candidates to protect against SARS-CoV-2, as well as Zika, RSV and HIV. “We have had very good pre-clinical and clinical data for our HIV vaccine, where the insert that we put in encodes for the HIV virus,” explained Van Hoof. “These results were so encouraging that we decided, based on those data, to conduct a clinical proof-of-concept efficacy study in Sub-Saharan Africa, which is ongoing with 2,600 women.” He hopes that by late 2021 they will have initial results of that efficacy study.
The years Janssen spent developing these AdVac® viral vectors is also helping the company with the creation of a potential SARS-CoV-2 vaccine. They are pursuing the development of a non-replicating viral-vector vaccine, which contains a piece of DNA that codes for the coronavirus “spike” protein and leverages their AdVac® vaccine technology. Maria Grazia Pau, Senior Director, Compound Development Team Leader for HIV vaccine programmes at Janssen said: “We are frontrunners in using large-volume bioreactors to produce AdVac viral vectors, which is a great benefit. Plus, we have experience from our work on HIV and Ebola to conduct large studies like the ones necessary for developing a vaccine against COVID-19. Our work in these areas has also demonstrated the value of strong partnerships and collaboration, which is experience we are also leveraging for our SARS‑CoV-2 vaccine programme.”
Johan Van Hoof received his medical degree (cum laude) from the University of Antwerp, Belgium, and was a research fellow in the Department of Anatomy and Embryology at Rijksuniversitair Centrum Antwerpen, Belgium. He studied business management at Krauthammer International School and the International Executive Programme INSEAD, Fontainebleau, France.
Johan joined the Johnson & Johnson Family of Companies in April 2005 as Vice President, Data Management and Early Clinical Development. Following roles as Chief Operating Officer (COO) of Johnson & Johnson Pharmaceutical Research, LLC, and Head of the Global Development Organization, he was appointed Global Therapeutic Area Head for Infectious Diseases and Vaccines in 2010. Since 2011, he has been overseeing R&D at Janssen Vaccines as Managing Director.
Thiebaut R, Snape MD, Goldstein N, et al. Safety and immunogenicity of 2-dose Ebola vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo in a phase II clinical trial in Europe (EBOVAC2) – ECCMID Live.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.